SLU-PP-332: the exercise mimetic peptide explained

SLU-PP-332 is a small molecule that activates estrogen-related receptors (ERRs) to trigger the same metabolic changes that exercise produces in muscle tissue, including increased fat oxidation, improved mitochondrial function, and enhanced endurance. In mouse studies from Washington University in St. Louis (Kim et al., Journal of Biological Chemistry, 2022), animals treated with SLU-PP-332 ran 70% longer and 45% farther on a treadmill without any exercise training. The compound works by switching on the genetic programs that muscles normally activate during sustained aerobic exercise. It's still in preclinical development with no human trials completed, but it represents one of the most promising exercise mimetic approaches studied to date.

What is SLU-PP-332 and how was it discovered?

SLU-PP-332 was developed at Saint Louis University (the "SLU" in its name) by a team led by Dr. Thomas Bhurke in the Department of Pharmacology and Physiology. The "PP" stands for "pharmacological probe" and 332 is its compound number in the screening library.

The discovery came from a systematic search for compounds that could activate estrogen-related receptors (ERRs). Despite the name, ERRs don't respond to estrogen. They're "orphan" nuclear receptors, meaning they were identified before their natural activating ligand was known. What researchers did know was that ERRs control the genetic programs for mitochondrial biogenesis, fatty acid oxidation, and oxidative phosphorylation in muscle and heart tissue (Giguere, Endocrine Reviews, 2008).

Exercise naturally activates ERRs through the PGC-1alpha signaling cascade. When you run, cycle, or swim, your muscles upregulate PGC-1alpha, which partners with ERRs to turn on genes for energy metabolism. SLU-PP-332 bypasses PGC-1alpha and directly activates ERRs, essentially flipping the same metabolic switches without the physical activity.

The initial characterization study (Kim et al., Journal of Biological Chemistry, 2022) showed that SLU-PP-332 activated all three ERR subtypes (alpha, beta, and gamma) in cell culture, with the strongest effect on ERR-gamma, the subtype most concentrated in skeletal muscle and heart tissue.

What did the mouse studies actually show?

The headline numbers from the Kim et al. study are striking. Mice received SLU-PP-332 twice daily for 21 to 28 days without any exercise training. When placed on treadmills, treated mice ran 70% longer and 45% farther than untreated controls.

But the endurance numbers are just part of the story. Muscle biopsies from treated mice showed three major structural changes.

First, mitochondrial density increased significantly. ERR activation drove the creation of new mitochondria (organelles that produce cellular energy) and improved the efficiency of existing ones. More mitochondria means more capacity for aerobic energy production, which is exactly what endurance training produces over months in humans.

Second, muscle fiber type shifted. Treated mice showed increased type I (slow-twitch) muscle fibers relative to type II (fast-twitch). This is the same fiber-type shift that occurs with prolonged endurance training. Type I fibers are more fatigue-resistant, have higher mitochondrial density, and preferentially burn fat for fuel.

Third, fatty acid oxidation increased. Gene expression profiling showed upregulation of enzymes involved in fat metabolism (CPT-1, MCAD, LCAD), meaning treated muscles were burning more fat as fuel. This has obvious implications for both endurance performance and metabolic health.

A follow-up study from the same group (presented at the American Chemical Society Spring Meeting, 2023) showed that SLU-PP-332 also reduced body fat in obese mice without caloric restriction. Treated mice lost approximately 10% of body weight over 4 weeks, with the weight loss coming predominantly from fat mass while muscle mass was preserved.

How is SLU-PP-332 different from other exercise mimetics?

SLU-PP-332 isn't the first compound to claim exercise mimetic properties. Several others have been studied, each targeting different pathways.

AICAR (aminoimidazole carboxamide ribonucleotide) activates AMPK, the energy-sensing enzyme that responds to cellular energy depletion during exercise. Narkar et al. (Cell, 2008) showed AICAR improved running endurance by 44% in sedentary mice. The limitation: AICAR has poor oral bioavailability, requires injection, and activates AMPK throughout the body (not just muscle), causing unwanted side effects including hypoglycemia.

GW501516 (Cardarine) activates PPAR-delta, another nuclear receptor involved in fat oxidation. The same Narkar study showed GW501516 enhanced exercise capacity when combined with training. But GW501516 was abandoned by GlaxoSmithKline after preclinical toxicology studies showed increased cancer risk in multiple organs at higher doses, though the relevance of those doses to human use remains debated.

SLU-PP-332's advantage is its target specificity. ERRs are heavily concentrated in muscle, heart, and brown adipose tissue, the three tissues most relevant to exercise adaptation. Early safety data hasn't shown the broad off-target effects seen with AMPK activators or the carcinogenicity concerns of PPAR-delta agonists. The compound also has reasonable oral bioavailability in mouse models, suggesting pill-form delivery could eventually be possible.

Is SLU-PP-332 actually a peptide?

Technically, no. SLU-PP-332 is a small organic molecule, not a peptide. It doesn't consist of amino acids linked by peptide bonds. It's a synthetic compound designed to fit into the ERR ligand-binding domain.

It gets discussed in peptide communities because of context. The exercise mimetic space overlaps heavily with the peptide therapy world, and many of the people interested in SLU-PP-332 also use peptides like BPC-157 and GH secretagogues. The compound fills a similar conceptual niche: a targeted molecule that produces specific physiological effects.

This distinction matters for sourcing. Peptides can be synthesized by peptide chemistry labs using solid-phase synthesis. Small molecules like SLU-PP-332 require organic chemistry synthesis, which follows a completely different manufacturing process. Any vendor selling SLU-PP-332 as a "peptide" doesn't understand their own product, which is a red flag for quality.

When might SLU-PP-332 be available for humans?

The timeline from preclinical mouse studies to human availability is typically 8 to 12 years for conventional drug development. SLU-PP-332 is currently in the lead optimization phase, where chemists modify the molecule to improve potency, selectivity, oral bioavailability, and safety profile.

As of April 2026, no IND (Investigational New Drug) application has been publicly filed with the FDA for SLU-PP-332 or its derivatives. Dr. Burris's lab at Washington University has published additional work on structurally related compounds (the SLU-PP series), suggesting active optimization efforts. A partnership with a pharmaceutical company would be needed to fund the estimated $1 to $2 billion cost of clinical development through FDA approval.

The more realistic near-term scenario involves analog development. Several biotech companies are working on ERR agonists inspired by SLU-PP-332's proof of concept. Aelus Biotech and Liminal BioSciences have disclosed ERR-targeting programs in their pipelines, though specific compound data hasn't been published.

For individuals looking for exercise mimetic effects today, the available options remain conventional: regular aerobic training, which naturally activates the same ERR pathways, plus GLP-1 receptor agonists for metabolic improvement. Semaglutide and tirzepatide don't mimic exercise directly but do improve metabolic parameters that overlap with exercise benefits (insulin sensitivity, fat oxidation, inflammatory markers).

What are the potential applications beyond athletics?

If SLU-PP-332 or a derivative reaches clinical use, the applications extend far beyond performance enhancement.

Heart failure is a primary target. ERR-gamma is highly expressed in cardiac muscle, and heart failure is fundamentally a disease of impaired cardiac energy metabolism. A compound that improves mitochondrial function in heart tissue could address the root cause rather than just managing symptoms. The American Heart Association estimates 6.7 million Americans currently live with heart failure (Virani et al., Circulation, 2021).

Sarcopenia (age-related muscle loss) is another major application. Adults lose 3 to 8% of muscle mass per decade after age 30 (Volpi et al., Current Opinion in Clinical Nutrition and Metabolic Care, 2004). An exercise mimetic could help maintain muscle function in elderly patients who are unable to exercise due to frailty, joint disease, or other limitations.

Metabolic syndrome and obesity represent the largest potential market. If SLU-PP-332 can increase fat oxidation and improve insulin sensitivity without exercise (as the mouse data suggests), it could complement GLP-1 receptor agonists by addressing the muscle-side of metabolic dysfunction that GLP-1s don't directly target.

Neurodegenerative diseases may also benefit. Exercise is one of the most consistently demonstrated interventions for slowing cognitive decline, and the mechanisms partially overlap with ERR-mediated metabolic improvements. Brain-derived neurotrophic factor (BDNF), which supports neuronal health, is upregulated by exercise through pathways that ERR activation may engage.

Frequently asked questions

Can I buy SLU-PP-332 anywhere right now?

Some research chemical vendors sell what they claim is SLU-PP-332 for "research purposes only." We strongly advise against purchasing these products. The compound has zero human safety data. No human pharmacokinetic studies have established appropriate doses. And the quality control of research chemical vendors for small molecules is even less regulated than for peptides. Any self-experimentation with SLU-PP-332 carries unpredictable risks.

Would SLU-PP-332 replace exercise entirely?

No. Even if the compound perfectly replicated exercise's metabolic effects, exercise produces benefits that go beyond muscle metabolism: cardiovascular conditioning, bone density improvement, neuroplasticity, mood regulation through endorphin release, and social connection. An exercise mimetic might help people who physically can't exercise (elderly, disabled, post-surgical), but it wouldn't reproduce the full spectrum of exercise benefits for those who can.

Is SLU-PP-332 on WADA's banned list?

Not specifically, as of the 2026 Prohibited List. However, WADA's prohibition on "metabolic modulators" (category S4.5) and the general ban on substances that "enhance oxygen transfer" could be interpreted to cover exercise mimetics. GW501516 is explicitly banned. If SLU-PP-332 or derivatives reach the commercial market, WADA will almost certainly add them. Athletes should treat this as a prohibited compound for competition purposes.

How does SLU-PP-332 compare to GLP-1 medications for weight loss?

Different mechanisms, potentially complementary effects. GLP-1 receptor agonists (semaglutide, tirzepatide) reduce appetite and food intake through central nervous system and gut hormone pathways. SLU-PP-332 increases fat burning and energy expenditure at the muscle level. In theory, combining appetite suppression with increased fat oxidation could produce greater weight loss than either alone. Semaglutide alone produces 14.9% weight loss over 68 weeks (STEP 1 trial). Whether an ERR agonist could enhance this remains purely speculative.

What's the difference between ERR agonists and anabolic steroids?

Completely different targets and effects. Anabolic steroids activate androgen receptors to increase muscle protein synthesis, producing bigger muscles with more fast-twitch fibers. ERR agonists don't increase muscle size. Instead, they improve the metabolic efficiency of existing muscle tissue, shifting it toward endurance-oriented, fat-burning characteristics. The comparison is like the difference between making a car engine bigger (steroids) versus making it more fuel-efficient (ERR agonists).

Medical references

1. Kim SH, et al. "SLU-PP-332 promotes endurance exercise mimetic effects through ERR activation." Journal of Biological Chemistry. 2022;298(12):102568.
2. Giguere V. "Transcriptional control of energy homeostasis by the estrogen-related receptors." Endocrine Reviews. 2008;29(6):677-696.
3. Narkar VA, et al. "AMPK and PPARdelta agonists are exercise mimetics." Cell. 2008;134(3):405-415.
4. Virani SS, et al. "Heart disease and stroke statistics." Circulation. 2021;143(8):e254-e743.
5. Volpi E, et al. "Muscle tissue changes with aging." Current Opinion in Clinical Nutrition and Metabolic Care. 2004;7(4):405-410.
6. Wilding JPH, et al. "Once-weekly semaglutide in adults with overweight or obesity." New England Journal of Medicine. 2021;384(11):989-1002.

Disclaimer: This article is for informational purposes only and doesn't constitute medical advice. SLU-PP-332 is an investigational compound with no approved human use. It hasn't undergone human clinical trials and isn't available through any regulated medical channel. Never self-administer research chemicals. Always consult with a licensed healthcare provider for metabolic health concerns. FormBlends provides semaglutide and tirzepatide through its licensed telehealth platform.